BPRC’s TB researchers team up with the global Collaboration for TB Vaccine Discovery
9 December 2015
BPRC has been selected as one of the expert centres for the “Collaboration for Tuberculosis Vaccine Discovery” that was recently initiated by the Bill & Melinda Gates Foundation.
Last summer, July 2015, the Bill & Melinda Gates Foundation (BMGF) has kicked off the Collaboration for Tuberculosis Vaccine Discovery (CTVD) by organising a meeting at its campus in Seattle which brought together over 50 participants and stakeholders in TB vaccine development. Prior to the meeting, BPRC was identified as an expert centre in non-human primate tuberculosis (TB) research and is now participating as a Central Service Facility to the CTVD for preclinical TB vaccine research and efficacy evaluation. BPRC has signed up to the Open Access policy of the BMGF, reinforcing the global effort towards the development of a new and more efficacious vaccination strategy against TB.
While building upon its TB and immune research capacities, BPRC will also implement with support of CTVD and partners a PET/CT imaging facility. PET/CT imaging enables the assessment of the host and pathogen interaction over time. This advanced, high resolution imaging capacity shall refine and strengthen preclinical TB research at BPRC.